Treatment of Lennox-Gastaut syndrome: Current recommendations

CNS Drugs

Volumn 10, Issue 3, 1998, Pages 181-188

  Delanty, Norman ^a   French, Jacqueline ^a,b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FELBAMATE; LAMOTRIGINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE;

ANTICONVULSANT THERAPY; CORPUS CALLOSUM; DIET THERAPY; HUMAN; KETOGENESIS; LENNOX GASTAUT SYNDROME; PRIORITY JOURNAL; REVIEW; VAGUS NERVE;

EID: 0031783133     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199810030-00003     Document Type: Review

References (59)

1. Lennox WG. The petit mal epilepsies: their treatment with tridione. JAMA 1945; 129: 1069-74
2. Gastaut H, Roger J, Soulayrol R, et al. Childhood epileptic encephalopathy with diffuse slow spike waves (otherwise known as 'petit mal variant') or Lennox syndrome. Epilepsia 1966; 7: 139-79
3. Commission on Classification and Terminology of the International League Against Epilepsy. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989; 30: 389-99
4. Aicardi J. Epileptic encephalopathies of early childhood. Curr Opin Neurol Neurosurg 1992; 5: 344-8
5. Dulac O, N'Guyen T. The Lennox-Gastaut syndrome. Epilepsia 1993; 34 Suppl. 7: S7-17
6. Glauser TA. Pediatric epilepsy syndromes. Curr Opin Pediatr 1995; 7: 640-9
7. Bednarek N, Motte J, Soukfflet C, et al. Evidence of late-onset infantile spasms. Epilepsia 1998; 39: 55-60
8. Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities: III. U.S. experience since 1986. Neurology 1996; 46: 465-9
9. Dimario FJ, Clancy RR. Paradoxical precipitation of tonic seizures by lorazepam in a child with atypical absence seizures. Pediatr Neurol 1988; 4: 249-51
10. Munn R, Farrell K. Open study of clobazam in refractory epilepsy. Pediatr Neurol 1993; 9: 465-9
11. Farrell K. Symptomatic generalized epilepsy and Lennox-Gastaut syndrome. In: Wyllie E, editor. The treatment of epilepsy: principles and practice. 2nd ed. Baltimore: Williams and Wilkins, 1996: 530-9
12. Group for the Evaluation of Cinromide in the Lennox-Gastaut Syndrome. Double-blind, placebo-controlled evaluation of cinromide in patients with the Lennox-Gastaut syndrome. Epilepsia 1989; 30: 422-9
13. Gram L. Pharmacokinetics of new antiepileptic drugs. Epilepsia 1996; 37 Suppl. 6: S12-6
14. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-65
15. Felbamate Study Group in Lennox-Gaustaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N Engl J Med 1993; 328: 29-33
16. Dodson WE. Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial. Epilepsia 1993; 34 Suppl. 7: S18-24
17. Bourgeois BF. Felbamate. Semin Pediatr Neurol 1997; 4: 3-8
18. Meldrum BS. Update on the mechanism of action of antiepileptic drugs. Epilepsia 1996; 37 Suppl. 6: S4-11
19. Smith SE, Meldrum BS. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Stroke 1995; 26: 117-22
20. Schlumberger E, Chavez F, Palacios L, et al. Lamotrigine in treatment of 120 children with epilepsy. Epilepsia 1994; 35: 359-67
21. Donaldson JA, Glauser TA, Olberding LS. Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox-Gastaut syndrome). Epilepsia 1997; 38: 68-73
22. Farrell K, Connolly MB, Munn R, et al. Prospective, open-label, add-on study of lamotrigine in 56 children with intractable generalized epilepsy. Pediatr Neurol 1997; 16: 201-5
23. Motte J, Trevathan E, Arvidsson JFV, et al. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. N Engl J Med 1997; 337: 1807-12
24. Wadelius M, Karlsson T, Wadelius C, et al. Lamotrigine and toxic epidermal necrolysis [letter]. Lancet 1996; 348: 1041
25. Mitchell P. Paediatric lamotrigine use hit by rash reports [news]. Lancet 1997; 349: 1080
26. Besag FM, Dulac O, Alving J, et al. Long-term safety and efficacy of lamotrigine (Lamictal) in pediatric patients with epilepsy. Seizure 1997; 6: 51-6
27. French JA, Bourgeois BFD, Dreifus FE, et al. An open-label multicenter study of topiramate in patients with the Lennox-Gastaut syndrome [abstract]. Neurology 1995; 45 Suppl. 4: A250
28. Glauser TA. Preliminary observations on topiramate in pediatric epilepsies. Epilepsia 1997; 38 Suppl. 1: S37-41
29. Guerreiro MM, Manreza ML, Guerreiro CA, et al. A pilot study of topiramate in children with Lennox-Gastaut syndrome [abstract]. Neurology 1997; 48 Suppl.: A39
30. Fisher R, Blum D. Clobazam, oxcarbazepine, tiagabine, topiramate, and other new antiepileptic drugs. Epilepsia 1995; 36 Suppl. 2: S105-14
31. Feucht M, Brantner-Inthaler S. Gamma-vinyl-GABA (vigabatrin) in the therapy of Lennox-Gastaut syndrome: an open study. Epilepsia 1994; 35: 993-8
32. Gibbs J, Appleton RE, Rosenbloom L. Vigabatrin in intractable childhood epilepsy: a retrospective study. Pediatr Neurol 1992; 8: 338-40
33. Appleton RE. Vigabatrin in the management of generalized seizures in children. Seizure 1995; 4: 45-8
34. Lopez-Valdes E, Hernandez-Lain A, Simon R, et al. Treatment of refractory infantile epilepsy with vigabatrin in a series of 55 patients [in Spanish]. Rev Neurol 1996; 24: 1255-7
35. Shields WD, Sanker R. Vigabatrin. Semin Pediatr Neurol 1997; 4: 43-50
36. Chiron C, Dumas C, Jambaque I, et al. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997; 26: 389-95
37. Graham D. Neuropathology of vigabatrin. Br J Clin Pharmacol 1989; 27 Suppl. 1: 43S-5S
38. Mauguiere F, Chauvel P, Dewailly J, et al. No effect of long-term vigabatrin treatment on central nervous system conduction in patients with refractory epilepsy: results of a multicenter study of somatosensory and visual evoked potentials. Epilepsia 1997; 39: 301-8
39. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-8
40. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87
41. Sakamato K, Kurokawa T, Tomita S, et al. Effects of zonisamide in children with epilepsy. Curr Ther Res 1988; 43: 378-83
42. Vossler DG. Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin. Neurology 1996; 46: 852-3
43. Duse M, Notarangelo LD, Tiberti S, et al. Intravenous immune globulin in the treatment of intractable childhood epilepsy. Clin Exp Immunol 1996; 104 Suppl. 1: 71-6
44. van Engelen BGM, Renier WO, Weemaes CMR, et al. High-dose intravenous immunoglobulin treatment in cryptogenic West and Lennox-Gastaut syndrome: an add-on study. Eur J Pediatr 1994; 153: 762-9
45. Illum N, Taudorf K, Heilmann C, et al. Intravenous immunoglobulin: a single-blind trial in children with Lennox-Gastaut syndrome. Neuropediatrics 1990; 21: 87-90
46. Gross-Tsur V, Shalev RS, Kazir E, et al. Intravenous high-dose gammaglobulins for intractable childhood epilepsy. Acta Neurol Scand 1993; 88: 204-9
47. Wheless JW. The ketogenic diet: fa(c)t or fiction. J Child Neurol 1995; 10: 419-23
48. Nordli Jr DR, De Vivo DC. The ketogenic diet revisited: back to the future. Epilepsia 1997; 38: 743-9
49. Kinsman SL, Vining EP, Quaskey SA, et al. Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases. Epilepsia 1992; 33: 1132-6
50. Fisher RS, Krauss GL, Ramsey E, et al. Assessment of vagus nerve stimulation for epilepsy: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 1997; 49: 293-7
51. Hornig GW, Murphy JV, Schallert G, et al. Left vagus nerve stimulation in children with refractory epilepsy. South Med J 1997; 90: 484-8
52. Chugani HT, Shewmon DA, Shields WD, et al. Surgery for intractable infantile spasms: neuroimaging perspectives. Epilepsia 1993; 34: 764-71
53. Chugani HT. The role of PET in childhood epilepsy. J Child Neurol 1994; 9 Suppl. 1: S82-8
54. Sakas DE, Philips J. Anterior callosotomy in the management of intractable epileptic seizures: significance of the extent of resection. Acta Neurochir 1996; 138: 700-7
55. Minguez-Castellanos A, Sanchez-Alvarez JC, Altuzarra A, et al. Callosotomy in the treatment of drug-resistant epilepsy [in Spanish]. Rev Neurol 1996; 24: 539-48
56. Schwartkroin PA. Origins of the epileptic state. Epilepsia 1997; 38: 853-8
57. Davies JA. Remacemide hydrochloride: a novel antiepileptic agent. Gen Pharmacol 1997; 28: 499-502
58. Hurd RW, Wilder BJ, Helveston WR, et al. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology 1996; 47: 1264-8
59. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997; 277: 805-8